Genotype-Guided P2Y12 Inhibitor Monotherapy in High Bleeding Risk Patients

6 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Brenden S. Ingraham, MD, an Interventional Cardiologist at Mayo Clinic in Rochester, MN, reviews his article appearing in the January 2025 issue of Mayo Clinic Proceedings, where using genotyping, he and his colleagues were able to identify a percentage of the population who could safely be managed using a single treatment regimen – Clopridogrel (Plavix) following percutaneous coronary intervention (PCI) if instituted within one week of the procedure. Dr. Ingraham notes this eliminated the need for dual use of aspirin, thus further reducing the risk of post-procedure bleeding. This can occur in approximately 1 in 20 post PCI patients following dual antiplatelet therapy who are readmitted for bleeding, with the highest incidence occurring within 30 days of discharge. Available at: https://mayocl.in/3ZhIvjA
Category
Cardiology
Be the first to comment

Up Next